Back to Journals » Therapeutics and Clinical Risk Management » Volume 14

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

Total article views   Abstract views HTML views PDF downloads Totals
19,984 Dovepress* 7,625 2,282+ 2,166 9,907
PubMed Central* 0 10,077 1,765 10,077
Totals 7,625 12,359 3,931 19,984
*Since 20 July 2018
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
1 0 0 0 0 1

View citations on PubMed Central and Google Scholar